Pacira BioSciences (PCRX) | Stock Overview & Key Data
Pacira BioSciences Performance Comparison
Stock Range
Today's Range
Low: $25.23
High: $25.94
on August 22, 2025
52 Week Range
Low: $12.61
High: $27.64
on September 12, 2024
on April 8, 2025
All-Time High: $121.95 on February 23, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.1B
EPS
-2.75
P/E Ratio (TTM)
13.14
Forward P/E
8.38
P/B Ratio
1.50
PEG Ratio
-0.10
Div. Yield
N/A
ROE
-15.57%
Beta
0.481
Debt to Equity
83.32
Financial Highlights
Profitability
Gross Margin
77.43%
Operating Margin
5.04%
Profit Margin
-18.06%
Returns and Earnings
Return on Assets (TTM)
2.69%
Return on Equity (TTM)
-15.57%
EBITDA
$171.8M
Net Income (TTM)
$-127.5M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$15.26
Quarterly Revenue Growth (YoY)
1.70%
Quarterly Earnings Growth (YoY)
1.73%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Pacira BioSciences PCRX | 1.14B Small-cap | 4.28% | 15.20% | -0.88% | 2.34% | 40.97% | 82.10% | -52.20% | -57.50% |
| Zoetis ZTS | 65.30B Large-cap | 4.59% | 0.82% | -3.89% | -1.51% | -5.23% | -16.11% | -9.09% | -2.69% |
| Haleon Plc - ADR HLN | 44.69B Large-cap | 1.76% | 1.76% | -11.21% | -3.25% | 4.03% | -0.81% | 57.62% | 32.52% |
| Ani Pharmaceuticals ANIP | 1.98B Small-cap | 4.05% | 37.19% | 58.91% | 63.78% | 64.16% | 47.58% | 139.55% | 191.20% |
| BioCryst BCRX | 1.76B Small-cap | 2.27% | -1.04% | -17.61% | 3.26% | 9.32% | 5.68% | -39.97% | 115.62% |
| BGM BGM | 1.51B Small-cap | 5.94% | -20.12% | -37.54% | -19.64% | -10.29% | 33.68% | 29.26% | -82.13% |
Ownership & Short Interest
Insider Ownership
1.82%
Institutional Ownership
115.95%
Shares Short
6M
Short Ratio
9.86
Short % of Shares Outstanding
18.20%
Average 10-Day Volume
724K
Average 90-Day Volume
735K
Pacira BioSciences Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Pacira BioSciences would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PCRX's 52-week high and low?
- In the last 52 weeks, Pacira BioSciences reached a high of $27.64 (on April 8, 2025) and a low of $12.61 (on September 12, 2024).
- What is the market cap and P/E ratio for PCRX?
- Curious about Pacira BioSciences's size and valuation? Its market capitalization stands at 1.14B. When it comes to valuation, the P/E ratio (trailing twelve months) is 13.14, and the forward P/E (looking ahead) is 8.38.
- Does PCRX pay dividends? If so, what's the yield?
- As for dividends, Pacira BioSciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Pacira BioSciences's main competitors or similar companies to consider before investing?
When looking at Pacira BioSciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS65.30B Healthcare Drug Manufacturers - Specialty & Generic -16.11% -9.09% Haleon Plc - ADR
HLN44.69B Healthcare Drug Manufacturers - Specialty & Generic -0.81% 57.62% Ani Pharmaceuticals
ANIP1.98B Healthcare Drug Manufacturers - Specialty & Generic 47.58% 139.55% BioCryst
BCRX1.76B Healthcare Drug Manufacturers - Specialty & Generic 5.68% -39.97% BGM
BGM1.51B Healthcare Drug Manufacturers - Specialty & Generic 33.68% 29.26% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Pacira BioSciences Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Pacira BioSciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -15.57%, the Debt to Equity ratio from the most recent quarter is 83.32, and its Gross Profit Margin stands at 77.43%.
- What is the recent revenue and earnings growth for PCRX?
- Looking at Pacira BioSciences's growth, its revenue over the trailing twelve months (TTM) was $706M. Compared to the same quarter last year (YoY), quarterly revenue grew by 1.70%, and quarterly earnings saw a YoY growth of 1.73%.
- How much of PCRX stock is held by insiders and institutions?
- Wondering who owns Pacira BioSciences stock? Company insiders (like executives and directors) hold about 1.82% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 115.95%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.